BioCentury | Jun 23, 2020
Product Development

June 22 Quick Takes: Invitae acquiring ArcherDX; plus lymphoma approval for Karyopharm, Merck, Nabriva, Myovant, Assembly-AbbVie, Genentech and more

ArcherDX picks deal with Invitae over IPO Genetic testing company Invitae (NYSE:NVTA) is acquiring ArcherDX Inc., adding a cancer diagnostics platform to its precision oncology business. ArcherDX’s shareholders will receive $325 million in cash plus...
BioCentury | Jun 20, 2020
Product Development

Regeneron’s commercial future

As its long-standing tie-up with Sanofi winds down, the main loss Regeneron faces is access to the pharma’s commercial footprint, as the biotech has yet to build one for itself. An analysis of Regeneron’s wholly...
BioCentury | May 28, 2020
Product Development

May 27 Quick Takes: EC approves Zeposia in RRMS; plus Dupixent approved in children, La Jolla, Shionogi, Alnylam and Bold

EC approves Zeposia ozanimod for relapsing-remitting MS The European Commission approved Zeposia ozanimod from Bristol Myers Squibb Co. (NYSE:BMY) to treat relapsing-remitting multiple sclerosis (RRMS). FDA approved the S1P receptor modulator in March for relapsing...
BioCentury | May 27, 2020

Sanofi's sale of Regeneron stake for $11B could set stage for both companies' growth through M&A

More than 16 years and five product launches after closing its first deal with Regeneron, Sanofi has sold its holding of roughly 20% of the biotech's shares for about $11.1 billion. While the French pharma...
BioCentury | May 21, 2020

HotSpot heads for clinic with $65M series B round to develop allosteric modulators

Allostery company HotSpot has added strategic and crossover investors to the mix for a $65 million series B round designed to take two small molecules into the clinic, but the company believes it will still...
BioCentury | May 5, 2020

Alexion sees opportunity in slow-selling Andexxa, buys Portola for $1.4B

With its purchase of hematology company Portola at a triple-digit premium, Alexion is signaling that it believes its commercial expertise can boost sales of Factor Xa reversal agent Andexxa/Ondexxya to meet expectations where Portola had...
BioCentury | Mar 5, 2020
Politics, Policy & Law

JAMA studies slam drug prices vs R&D costs, Merck’s Frazier pushes back

A series of JAMA studies calls out the disconnect between the cost to develop new drugs and rising drug prices, but according to Merck’s Kenneth Frazier the analyses used flawed assumptions, non-representative data sets, and...
BioCentury | Jan 29, 2020
Company News

Jan. 28 Company Quick Takes: Kite, Alkermes, Regeneron-Sanofi, Incyte, NantHealth-NantOmics, Sorrento, MicroCures, Paion-Mundipharma

Kite’s KTE-X19 under review in Europe EMA has accepted an MAA for KTE-X19 from Kite, positioning the CAR T cell therapy from the Gilead Sciences Inc. (NASDAQ:GILD) unit to become the first CAR T cell...
BioCentury | Jan 22, 2020
Company News

Despite outreach to over 18 companies, Lilly was only biopharma to offer Dermira takeout

Dermira’s multiyear quest to find a partner for lebrikizumab found it knocking on the doors of over 18 biopharmas, but only Eli Lilly was interested in submitting a bid to acquire the autoimmune and dermatology...
BioCentury | Jan 10, 2020
Company News

Lilly bolsters atopic dermatitis arsenal via $1.1B Dermira deal, gaining Dupixent challenger

Via its $1.1 billion takeout of Dermira on Friday, Eli Lilly added to its late-stage pipeline an atopic dermatitis therapy that could challenge Dupixent. The price -- $18.75 per share -- is a premium of...
Items per page:
1 - 10 of 118